Numerous studies [6–8] have demonstrated that the pathophysiological process for the development of SLE are closely associated with the mutation and abnormal expression of genes, which include TNFSF4, NCF1-339, CXorf21, etc. A previous study demonstrated that IFI44L promoter methylation as a blood biomarker for systemic lupus erythematosus [9]. This evidence concerns the gene IFI44L and systemic lupus erythematosus.